公开(公告)号：US20220098318A1

公开(公告)日：2022-03-31

申请号：US17411638

申请日：2021-08-25

Applicant: Genentech, Inc.

Inventor： Raymond D. MENG ,  Robert Wenchen HSIEH ,  Namrata Srivastava PATIL ,  Sean Keith KELLEY ,  Karen Lynn KLING-MILLER ,  William Michael FLANAGAN

IPC: C07K16/28 ,  A61P35/00

Abstract: The invention provides methods of dosing for the treatment of cancers. In particular, provided are methods for treating human patients having cancer, such as a hematologic cancer, by administering a combination of an anti-TIGIT antagonist antibody and an anti-CD20 antibody or anti-CD38 antibody.

公开(公告)号：US20240327519A1

公开(公告)日：2024-10-03

申请号：US18424297

申请日：2024-01-26

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Henry KAO ,  Christoph MARKERT ,  Christine MCINTYRE ,  Raymond D. MENG ,  Merlind MUECKE ,  Volker TEICHGRAEBER ,  Laura CODARRI DEAK

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/22

CPC classification number: C07K16/2818 ,  C07K16/22 ,  C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/90

Abstract: This invention relates to methods and compositions for use in treating cancer in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG3).

公开(公告)号：US20220324981A1

公开(公告)日：2022-10-13

申请号：US17704878

申请日：2022-03-25

Applicant: Genentech, Inc.

Inventor： Raymond D. MENG ,  Namrata Srivastava PATIL ,  William Michael FLANAGAN

IPC: C07K16/28 ,  A61P35/04 ,  C12Q1/6886

Abstract: The invention provides methods of dosing for the treatment of cancers. In particular, provided are methods for treating human patients having lung cancer, such as non-small cell lung cancer (NSCLC), by administering a combination of an anti-TIGIT antagonist antibody and a PD-1 axis binding antagonist.

公开(公告)号：US20220016243A1

公开(公告)日：2022-01-20

申请号：US17159128

申请日：2021-01-26

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Catherine LAI ,  Janet LAU ,  Anthony Jongha LEE ,  Shi LI ,  Yvonne Gail LIN-LIU ,  Christina Jeanne MATHENY ,  Diana MENDUS ,  Raymond D. MENG ,  Anh NGUYEN DUC ,  Jilpa Bhupendra PATEL ,  Thinh Quang PHAM ,  Isabelle Anne ROONEY ,  Heather Blythe STEVENS ,  Sarah Marie TROUTMAN ,  Lijia WANG ,  Yulei WANG ,  Patrick Georges Robert WILLIAMS ,  Benjamin WU ,  Yibing YAN ,  Aijing ZHANG ,  Xiaosong ZHANG ,  Marcus Dale BALLINGER ,  Hila BARAK ,  Elizabeth Alexandra BENNETT ,  Marcela Lucia CASTRO ,  Edward Namserk CHA ,  Hui Min Phyllis CHAN ,  Stephen CHUI ,  Christopher Roland COTTER ,  Viraj Vinay DEGAONKAR ,  Barbara Jennifer GITLITZ ,  Tien HOANG ,  Kimberly Mayumi KOMATSUBARA

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/282 ,  A61K31/7048 ,  A61K31/519 ,  A61K31/7068 ,  A61K31/337 ,  A61K38/19 ,  A61K47/60 ,  A61K31/675 ,  A61P35/04 ,  A61K33/243 ,  A61K47/68 ,  A61K31/513 ,  C07K16/28

Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.

公开(公告)号：US20240424092A1

公开(公告)日：2024-12-26

申请号：US18754676

申请日：2024-06-26

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Catherine LAI ,  Janet LAU ,  Anthony Jongha LEE ,  Shi LI ,  Yvonne Gail LIN-LIU ,  Christina Jeanne MATHENY ,  Diana MENDUS ,  Raymond D. MENG ,  Anh NGUYEN DUC ,  Jilpa Bhupendra PATEL ,  Thinh Quang PHAM ,  Isabelle Anne ROONEY ,  Heather Blythe STEVENS ,  Sarah Marie TROUTMAN ,  Lijia WANG ,  Yulei WANG ,  Patrick Georges Robert WILLIAMS ,  Benjamin WU ,  Yibing YAN ,  Aijing ZHANG ,  Xiaosong ZHANG ,  Marcus Dale BALLINGER ,  Hila BARAK ,  Elizabeth Alexandra BENNETT ,  Marcela Lucia CASTRO ,  Edward Namserk CHA ,  Hui Min Phyllis CHAN ,  Stephen CHUI ,  Christopher Roland COTTER ,  Viraj Vinay DEGAONKAR ,  Barbara Jennifer GITLITZ ,  Tien HOANG ,  Kimberly Mayumi KOMATSUBARA

IPC: A61K39/395 ,  A61K31/282 ,  A61K31/337 ,  A61K31/513 ,  A61K31/519 ,  A61K31/675 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/243 ,  A61K38/19 ,  A61K39/00 ,  A61K47/60 ,  A61K47/68 ,  A61P35/00 ,  A61P35/04 ,  C07K16/28

Abstract: The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.

公开(公告)号：US20240287182A1

公开(公告)日：2024-08-29

申请号：US18402031

申请日：2024-01-02

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Christoph MARKERT ,  Raymond D. MENG ,  Merlind MUECKE ,  Shiraj SEN ,  Volker TEICHGRAEBER ,  Volker Andreas WIEBKING ,  Edward Namserk CHA ,  Christopher Roland COTTER ,  Michelle Yuri DORAL

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/04

CPC classification number: C07K16/2818 ,  A61P35/04 ,  C07K16/2803 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/76

Abstract: This invention relates to methods and compositions for use in treating cancer in a subject. For example, the invention relates to methods and compositions for use in treating esophageal cancer or colorectal cancer (CRC) (e.g., metastatic CRC (e.g., microsatellite instability (MSI) high (MSI-H) metastatic CRC)) in a subject by administering to the subject an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab); methods and compositions for use in treating metastatic CRC (e.g., MSI-H metastatic CRC) in a subject by administering to the subject an anti-TIGIT antagonist antibody (e.g., tiragolumab), a PD-1 axis binding antagonist (e.g., atezolizumab), and an anti-VEGF antibody (e.g., bevacizumab); methods and compositions for use in treating melanoma in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG3), optionally with an anti-TIGIT antagonist antibody (e.g., tiragolumab); and methods and compositions for use in treating a CD20-positive cell proliferative disorder (e.g., non-Hodgkin's lymphoma (NHL); e.g., relapsed or refractory NHL) in a subject by administering to the subject a bispecific antibody targeting CD20 and CD3 (mosunetuzumab) and an anti-TIGIT antagonist antibody (e.g., tiragolumab), optionally with a PD-1 axis binding antagonist (e.g., atezolizumab).